TLR4 and non-small cell lung carcinoma: In oncology and surgical fields, the TLR4 inhibitor TAK-242 combined with estrogen antagonist Fulvestrant inhibits non-small cell lung cancer metastasis (198), while a compound formulation of TAK-242 with hyaluronic acid reduces postoperative abdominal adhesion incidence by 64% in mice through TLR4/ROS signaling inhibition (199).